Allergan Aesthetics

Allergan Aesthetics is the medical-aesthetics franchise of the pharmaceutical company AbbVie. It brings together the aesthetic and injectable portfolio historically assembled under Allergan — most famously Botox (botulinum toxin type A), along with dermal fillers such as the Juvéderm family, and a wider set of facial-aesthetics, skin-care and body-contouring brands. The business sells primarily to physicians, dermatologists, plastic surgeons and medically supervised aesthetic clinics rather than directly to consumers, and it operates across the United States and many international markets. The brand's identity is closely tied to the modern medical-aesthetics category. Allergan built a leading position in aesthetic medicine through Botox and its filler portfolio, and when AbbVie acquired Allergan in 2020 the aesthetics operations were carried forward as a distinct business unit, Allergan Aesthetics. That unit markets itself as a partner to aesthetic practitioners, combining product brands with training, clinical education and practice-support programs. Positioning centers on physician-administered, regulated aesthetic treatments — a medically framed alternative to cosmetic surgery and consumer beauty products. The portfolio spans neuromodulators, hyaluronic-acid fillers, skin-care lines and related devices, giving the business a broad presence across facial rejuvenation and body aesthetics. Because it sits inside a large pharmaceutical group, Allergan Aesthetics is a subsidiary rather than an independently listed company, and its commercial strategy is shaped by AbbVie's broader corporate priorities.

Allergan Aesthetics traces its roots to Allergan, the eye-care and specialty-pharmaceutical company that over decades expanded into aesthetic medicine. The pivotal product was Botox: botulinum toxin type A, first developed for medical uses such as strabismus and blepharospasm, which became a cultural and commercial phenomenon after its cosmetic use for facial wrinkles took off. Botox became one of the most recognized brand names in medicine and the anchor of Allergan's aesthetics business. Allergan broadened the franchise beyond neuromodulators. It acquired and developed a portfolio of hyaluronic-acid dermal fillers marketed under the Juvéderm name, along with other facial-aesthetics products, skin-care brands and body-contouring offerings. Together these made Allergan a leading player in the fast-growing medical-aesthetics market, selling to dermatologists, plastic surgeons and aesthetic clinics worldwide. A major turning point came in 2020, when the pharmaceutical company AbbVie completed its acquisition of Allergan. The combined group kept the aesthetics operations as a distinct business, branded Allergan Aesthetics, sitting alongside AbbVie's other therapeutic areas. This structure allowed the aesthetics portfolio to retain its own commercial identity and specialist sales and training organization while benefiting from the scale and resources of a larger parent. In the years since, Allergan Aesthetics has continued to position itself as a comprehensive partner to aesthetic practitioners, emphasizing clinical education, training programs and a broad portfolio spanning injectables, skin care and related treatments. The business operates across the United States and numerous international markets, and its brands remain among the most widely known in aesthetic medicine.

• AbbVie completes its acquisition of Allergan, with the aesthetics operations carried forward as Allergan Aesthetics.

Physician-administered, regulated medical-aesthetics treatments positioned between cosmetic surgery and consumer beauty.

• Botox

  Botulinum toxin type A, the flagship neuromodulator brand.

• Juvéderm

  Family of hyaluronic-acid dermal fillers.

• 2026.08.15

  Reported2026.08.15

  Allergan Aesthetics and Deloitte China release 2026 China Medical Aesthetics Industry Insight Report[1]艾尔建美学联合德勤中国发布《中国医美行业2026年度洞悉报告》prnasia.com

  Allergan Aesthetics and Deloitte China jointly released the 2026 China Medical Aesthetics Industry Insight Report, based on surveys of 2,000 consumers and 200 operators/doctors, forecasting China's medical aesthetics consumption market could exceed RMB 600 billion by 2030. The two parties have jointly published the annual report for five consecutive years.

Read more

1. 1艾尔建美学联合德勤中国发布《中国医美行业2026年度洞悉报告》prnasia.com